Recently, Luoxin Pharmaceutical announced that its subsidiary Shandong Luoxin and South Korea’s HK inno.N Corporation (formerly CJHealthCare Corporation) signed the "License Agreement" on June 23, 2021, and reached an agreement on the introduction of tegoprazan injection products. Xin will obtain the exclusive right to develop, produce and commercialize the product in China.

Tegoprazan is a potassium ion-competitive acid blocker (Potassium-Competitive Acid Blockers, P-CAB). Its mechanism of inhibiting acid secretion is to competitively bind potassium in the H+/K+-ATPase (proton pump) in parietal cells. Ion binding site. Different from traditional acid suppressant proton pump inhibitor (PPI), P-CAB can directly inhibit H+/K+-ATPase without activation in a strong acid environment. Moreover, whether H+/K+-ATPase is activated or not, P-CAB can bind to it.

Tegoprazan injection is mainly used for the treatment of gastroesophageal reflux, upper gastrointestinal bleeding and prevention of stress gastric mucosal damage, etc. It has fast onset, long action time, stability under acidic conditions, and can simultaneously inhibit activated and resting proton pumps, etc. Features. At present, tegoprazan injections have no products on the market globally, and Luoxin Pharmaceutical's introduction of tegoprazan, which is the first to deploy China's domestic PPIs market, ushered in an opportunity for them.

According to statistics, China's proton pump inhibitor (PPI) drugs have a huge clinical use, once occupying more than 80% of the market share of peptic ulcer drugs and 14.4% of the digestive and metabolic drugs market. In 2018, the terminal PPI injection market in China's public medical institutions reached 24 billion yuan, accounting for 3.9% of the domestic chemical drug injection market. In 2019, the terminal PPI injection market in China's public medical institutions has reached 40 billion yuan, and the domestic market will be about 30 billion yuan in 2020. The clinical market has an unprecedented prospect.

Following the introduction of tegoprazan injection products, Luoxin Pharmaceuticals has again spread good news, and its innovative drug tegoprazan tablets have made significant progress in the research and development. Subsidiary Shandong Luoxin Pharmaceutical Group Co., Ltd. received the LXI issued by the State Drug Administration -15028 tablets (Tigolasheng tablets) "Notice of Approval of Supplementary Application for Drug Clinical Trials", agreeing to carry out phase III clinical trials for duodenal ulcer indications.

At the same time as the introduction of tegoprazan injection, the clinical trial of tegoprazan tablets for new indications was approved, demonstrating Luoxin's strong research and development capabilities and clinical advancement capabilities, and looking forward to providing new options for acid suppression treatment as soon as possible.